mk2 Biotechnologies and Sartorius Stedim Biotech jointly develop next-generation production platform for biologics
The platform aims at sustainable and cost-efficient production of highly effective biologics on a large scale.
© mk2 Biotechnologies
Sartorius Stedim Biotech and mk2 joined forces to create the next-generation, low-cost biologics production platform.
mk2 Biotechnologies, a peptide and protein production specialist for large-scale applications, and Sartorius Stedim Biotech Corporate Research, a leading technology and solutions provider to the biotech/biopharma industry, announced at the end of June that they are joining forces to create the next-generation, low-cost biologics production platform. Integrating an intensified approach, the platform aims to make a ground-breaking step forward to facilitate sustainable and cost-efficient, large-scale production of high-efficacy biologics. The collaboration will pave new ways to meet the rising global bio-based API demands.
Biologicals include a wide range of products and can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. Biological products often represent the cutting-edge of biomedical research and may offer a highly effective means to treat a variety of medical conditions.
mk2 Biotechnologies develops, produces and investigates peptides at highest purity and quality standards using a revolutionary scalable synthesis technology. The start-up is able to synthesize any kind of authentic peptide, regardless of its physical or chemical properties. This includes arbitrary chain length, charge, polarity and hydrophobicity. For this reason, mk2 is strongly convinced that its process has the potential to tackle parts of major social challenges as well as to provide solutions for a known and yet unknown demand for new classes of active substances.
mk2 Biotechnologies enables high potential peptide-based products to become applicable for mass markets.
mk2, that emerged from an “EXIST Transfer of Research”, develops, produces and investigates peptides and proteins at highest purity and quality standards using a revolutionary scalable synthesis technology. This way mk2 Biotechnologies enables the production of peptides, regardless of their physical or chemical properties, at large scales and low cost. For more information, visit: www.mk2.bio